Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines

Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers. Albeit its incidence does not score among the highest in cancer, PDAC prognosis is tremendously fatal. As a result of either aggressiveness or metastatic stage at diagnosis, chemotherapy constitutes the only marginal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragone, Angela, Salzillo, Alessia, Spina, Annamaria, Naviglio, Silvio, Sapio, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902254/
https://www.ncbi.nlm.nih.gov/pubmed/35273510
http://dx.doi.org/10.3389/fphar.2022.837503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902254/
https://www.ncbi.nlm.nih.gov/pubmed/35273510
http://dx.doi.org/10.3389/fphar.2022.837503

Ejemplares similares